Abstract
This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiviral Agents / administration & dosage
-
Genotype
-
Hepacivirus / classification
-
Hepacivirus / genetics
-
Hepacivirus / isolation & purification*
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / virology*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Polyethylene Glycols / administration & dosage
-
Recombinant Proteins / administration & dosage
-
Recurrence
-
Ribavirin / administration & dosage
-
Risk Assessment
-
Viral Load*
-
Viremia*
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2b